Skip to main content
Erschienen in: World Journal of Urology 3/2015

01.03.2015 | Original Article

Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate

verfasst von: Satoshi Otsubo, Akira Yokomizo, Osamu Mochida, Masaki Shiota, Katsunori Tatsugami, Junich Inokuchi, Seiji Naito

Erschienen in: World Journal of Urology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recently, more vaporization techniques are available for the treatment of benign prostate hyperplasia (BPH). However, the detection of incidental prostate cancer (Pca) is impossible in vaporization techniques because of unavailability prostate tissue for histopathological analysis. To evaluate the clinical backgrounds and the usefulness of prostate-specific antigen (PSA)-related factors in incidental Pca, we employed our BPH patients cohort treated by holmium laser enucleation of the prostate (HoLEP).

Methods

A total of 365 HoLEPs were performed by a single surgeon. The pathological results and pre- and post-HoLEP PSA, PSA density and PSA velocity were analyzed retrospectively.

Results

Incidental Pca was identified in 25 (6.8 %) of the 365 patients treated with HoLEP. There were significant differences between BPH and Pca in terms of prostate volume (55.5 vs. 47 ml, p = 0.0365), preoperative PSA (4.50 vs. 7.14 ng/ml, p = 0.0107), PSA density (0.079 vs. 0.155 ng/ml/cm3, p = 0.0005), and postoperative PSA velocity (0.04 vs. 0.22 ng/ml/year, p = 0.0033), respectively. Comparisons of Gleason score subgroups in the 25 patients with incidental Pca identified significant differences in preoperative PSA (6.06 vs. 21.6 ng/ml, p = 0.0191) and postoperative PSA velocity (0.185 vs. 1.32 ng/ml/year, p = 0.0382) between the Gleason score 3 + 3 and Gleason score >3 + 3 groups, respectively.

Conclusions

Risk factors associated with incidental Pca were smaller prostate volume, higher preoperative PSA, and higher PSA density. Postoperative PSA velocity was also significantly increased in patients with incidental Pca, especially those with higher Gleason score. These finding may be useful in incident Pca patients treated by the vaporization technique.
Literatur
1.
Zurück zum Zitat Zigeuner RE, Lipsky K, Riedler I et al (2003) Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 62:451–455CrossRefPubMed Zigeuner RE, Lipsky K, Riedler I et al (2003) Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 62:451–455CrossRefPubMed
2.
Zurück zum Zitat Capitanio U, Scattoni V, Freschi M et al (2008) Radical prostatectomy for incidental (stage T1a–T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 54:118–125CrossRefPubMed Capitanio U, Scattoni V, Freschi M et al (2008) Radical prostatectomy for incidental (stage T1a–T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 54:118–125CrossRefPubMed
3.
Zurück zum Zitat Zhang G, Wasserman NF, Sidi AA, Reinberg Y, Reddy PK (1991) Long-term followup results after expectant management of stage A1 prostatic cancer. J Urol 146:99–102; discussion 102–103PubMed Zhang G, Wasserman NF, Sidi AA, Reinberg Y, Reddy PK (1991) Long-term followup results after expectant management of stage A1 prostatic cancer. J Urol 146:99–102; discussion 102–103PubMed
4.
Zurück zum Zitat Elzayat EA, Al-Mandil MS, Khalaf I, Elhilali MM (2009) Holmium laser ablation of the prostate versus photoselective vaporization of prostate 60 cc or less: short-term results of a prospective randomized trial. J Urol 182:133–138CrossRefPubMed Elzayat EA, Al-Mandil MS, Khalaf I, Elhilali MM (2009) Holmium laser ablation of the prostate versus photoselective vaporization of prostate 60 cc or less: short-term results of a prospective randomized trial. J Urol 182:133–138CrossRefPubMed
5.
Zurück zum Zitat Nunez R, Hurd KJ, Noble BN, Castle EP, Andrews PE, Humphreys MR (2011) Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol 18:543–547CrossRefPubMed Nunez R, Hurd KJ, Noble BN, Castle EP, Andrews PE, Humphreys MR (2011) Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol 18:543–547CrossRefPubMed
6.
Zurück zum Zitat Elmansy HM, Elzayat EA, Sampalis JS, Elhilali MM (2009) Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy. Urology 74:1105–1110CrossRefPubMed Elmansy HM, Elzayat EA, Sampalis JS, Elhilali MM (2009) Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy. Urology 74:1105–1110CrossRefPubMed
7.
Zurück zum Zitat Arlen PM, Bianco F, Dahut WL et al (2008) Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179:2181–2185; discussion 2185–2186CrossRefPubMedCentralPubMed Arlen PM, Bianco F, Dahut WL et al (2008) Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179:2181–2185; discussion 2185–2186CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Jones JS, Follis HW, Johnson JR (2009) Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostate Dis 12:57–60CrossRef Jones JS, Follis HW, Johnson JR (2009) Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostate Dis 12:57–60CrossRef
9.
Zurück zum Zitat Melchior S, Hadaschik B, Thuroff S, Thomas C, Gillitzer R, Thuroff J (2009) Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 103:1478–1481CrossRefPubMed Melchior S, Hadaschik B, Thuroff S, Thomas C, Gillitzer R, Thuroff J (2009) Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 103:1478–1481CrossRefPubMed
10.
Zurück zum Zitat Naspro R, Freschi M, Salonia A et al (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171:1203–1206CrossRefPubMed Naspro R, Freschi M, Salonia A et al (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171:1203–1206CrossRefPubMed
11.
Zurück zum Zitat Tinmouth WW, Habib E, Kim SC et al (2005) Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol 19:550–554CrossRefPubMed Tinmouth WW, Habib E, Kim SC et al (2005) Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol 19:550–554CrossRefPubMed
12.
Zurück zum Zitat Nomura H, Seki N, Yamaguchi A, Naito S (2009) Comparison of photoselective vaporization and standard transurethral resection of the prostate on urodynamics in patients with benign prostatic hyperplasia. Int J Urol 16:657–662 Nomura H, Seki N, Yamaguchi A, Naito S (2009) Comparison of photoselective vaporization and standard transurethral resection of the prostate on urodynamics in patients with benign prostatic hyperplasia. Int J Urol 16:657–662
13.
Zurück zum Zitat Hirasawa Y, Ide H, Yasumizu Y, Hoshino K, Ito Y, Masuda T (2012) Comparison of transurethral enucleation with bipolar and transurethral resection in saline for managing benign prostatic hyperplasia. BJU Int 110:E864–E869CrossRefPubMed Hirasawa Y, Ide H, Yasumizu Y, Hoshino K, Ito Y, Masuda T (2012) Comparison of transurethral enucleation with bipolar and transurethral resection in saline for managing benign prostatic hyperplasia. BJU Int 110:E864–E869CrossRefPubMed
14.
Zurück zum Zitat Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869–875CrossRefPubMedCentralPubMed Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869–875CrossRefPubMedCentralPubMed
Metadaten
Titel
Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate
verfasst von
Satoshi Otsubo
Akira Yokomizo
Osamu Mochida
Masaki Shiota
Katsunori Tatsugami
Junich Inokuchi
Seiji Naito
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 3/2015
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-014-1310-9

Weitere Artikel der Ausgabe 3/2015

World Journal of Urology 3/2015 Zur Ausgabe

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.